Quest Diagnostics (DGX) Long-Term Investments (2014 - 2026)

Quest Diagnostics has disclosed Long-Term Investments across 13 years of filings, most recently posting $134.0 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $134.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.0 million (changed 0.0% YoY), and the FY2025 annual result was $136.0 million, up 10.57% from the prior year.
• Long-Term Investments came in at $134.0 million for Q1 2026 at Quest Diagnostics, down from $136.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $155.0 million in Q1 2022 to a low of $123.0 million in Q4 2024.
• The 5-year median for Long-Term Investments is $134.0 million (2025), against an average of $134.4 million.
• Peak annual rise in Long-Term Investments reached 32.43% in 2022, while the deepest fall reached 70.59% in 2022.
• Quest Diagnostics' Long-Term Investments stood at $132.0 million in 2022, then gained by 2.27% to $135.0 million in 2023, then dropped by 8.89% to $123.0 million in 2024, then gained by 10.57% to $136.0 million in 2025, then declined by 1.47% to $134.0 million in 2026.
• The last three Long-Term Investments figures came in at $134.0 million (Q1 2026), $136.0 million (Q4 2025), and $137.0 million (Q3 2025), per Business Quant data.